Skip to content

VolitionRx Files New Patent for Nu.Q® NETs Test Aimed at Ebola Monitoring

VolitionRx Limited has filed a new patent for its Nu.Q® technology designed for triaging and monitoring patients suspected of contracting the Ebola virus. The Nu.Q® NETs test measures immune response indicators, offering a potential bedside triage solution, particularly in resource-constrained environments. The company seeks strategic partnerships to deploy its technology in outbreak areas.

Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by…